Matrix metalloproteinase: Difference between revisions

From Proteopedia
Jump to navigation Jump to search
Michal Harel (talk | contribs)
No edit summary
Michal Harel (talk | contribs)
No edit summary
Line 70: Line 70:


**[[1qia]], [[1qic]], [[1cqr]], [[1slm]] - hMMP catalytic domain<BR />  
**[[1qia]], [[1qic]], [[1cqr]], [[1slm]] - hMMP catalytic domain<BR />  
**[[3ohl]], [[3oho]], [[1g49]], [[1ciz]], [[1b8y]], [[1caq]], [[1usn]], [[2usn]], [[1ums]], [[1umt]],  [[2d1n]], [[2d1o]], [[2ow9]], [[1bqo]], [[1g4k]], [[1b3d]], [[1biw]], [[1c3i]], [[1d5j]], [[1d7x]], [[1d8f]], [[1d8m]], [[1g05]], [[1hfs]], [[1hy7]], [[2srt]], [[4dpe]], [[4g9l]], [[4ja1]] - hMMP catalytic domain + inhibitor<br />
**[[3ohl]], [[3oho]], [[1g49]], [[1ciz]], [[1b8y]], [[1caq]], [[1usn]], [[2usn]], [[1ums]], [[1umt]],  [[2d1n]], [[2d1o]], [[2ow9]], [[1bqo]], [[1g4k]], [[1b3d]], [[1biw]], [[1c3i]], [[1d5j]], [[1d7x]], [[1d8f]], [[1d8m]], [[1g05]], [[1hfs]], [[1hy7]], [[2srt]], [[4dpe]], [[4g9l]], [[4ja1]], [[5uwn]], [[5uwm]], [[5uwk]], [[5uwl]] - hMMP catalytic domain + inhibitor<br />
**[[1c8t]] - hMMP catalytic domain (mutant) + inhibitor<br />
**[[1c8t]] - hMMP catalytic domain (mutant) + inhibitor<br />
**[[1uea]] - hMMP catalytic domain + TIMP-1<BR />
**[[1uea]] - hMMP catalytic domain + TIMP-1<BR />
Line 81: Line 81:
**[[2mze]] – hpro-MMP (mutant)  - NMR<br />
**[[2mze]] – hpro-MMP (mutant)  - NMR<br />
**[[2mzh]], [[2mzi]] – hpro-MMP (mutant) + membrane bilayer - NMR<br />
**[[2mzh]], [[2mzi]] – hpro-MMP (mutant) + membrane bilayer - NMR<br />
**[[5ue5]], [[5ue2]] – hMMP (mutant) + heparin - NMR<br />


*MMP8 neutrophil collagenase
*MMP8 neutrophil collagenase
Line 93: Line 94:
**[[1l6j]] - pro-hMMP<BR />
**[[1l6j]] - pro-hMMP<BR />
**[[1itv]] – hMMP haemopexin-like domain<br />
**[[1itv]] – hMMP haemopexin-like domain<br />
**[[1gkc]], [[4xct]], [[4wzv]], [[5cuh]], [[5i12]] - hMMP catalytic domain + inhibitor<br />
**[[1gkc]], [[4xct]], [[4wzv]], [[5cuh]], [[5i12]], [[5ue4]], [[5ue3]], [[5th6]] - hMMP catalytic domain + inhibitor<br />
**[[2ovx]], [[2ovz]], [[2ow0]], [[2ow1]], [[2ow2]], [[1gkd]], [[4h1q]], [[4h82]], [[4hma]], [[4h2e]], [[4h3x]] - hMMP catalytic domain (mutant) + inhibitor<br />
**[[2ovx]], [[2ovz]], [[2ow0]], [[2ow1]], [[2ow2]], [[1gkd]], [[4h1q]], [[4h82]], [[4hma]], [[4h2e]], [[4h3x]], [[6esm]] - hMMP catalytic domain (mutant) + inhibitor<br />
**[[4jij]], [[4jqg]] - hMMP catalytic domain (mutant) + FRET substrate<br />
**[[4jij]], [[4jqg]] - hMMP catalytic domain (mutant) + FRET substrate<br />
**[[5th9]] - hMMP catalytic domain + antibody<br />


*MMP10 stromelysin 2
*MMP10 stromelysin 2
Line 115: Line 117:
**[[2jxy]] - hMMP hemopexin-like domain - NMR<BR />
**[[2jxy]] - hMMP hemopexin-like domain - NMR<BR />
**[[3n2u]], [[3n2v]], [[2wo8]], [[2wo9]], [[2woa]], [[1utt]], [[1utz]], [[1ros]], [[3rts]], [[3rtt]] – hMMP catalytic domain + inhibitor<br />
**[[3n2u]], [[3n2v]], [[2wo8]], [[2wo9]], [[2woa]], [[1utt]], [[1utz]], [[1ros]], [[3rts]], [[3rtt]] – hMMP catalytic domain + inhibitor<br />
**[[3lk8]], [[3lik]], [[3lil]], [[3lir]], [[3ljg]], [[3nx7]], [[3lka]], [[3ehx]], [[3ehy]], [[3f15]], [[3f16]], [[3f17]], [[3f18]], [[3f19]], [[3f1a]], [[1y93]], [[1rmz]], [[1os2]], [[1os9]], [[2hu6]], [[3ts4]], [[3tsk]], [[3uvc]], [[4gql]], [[4gr0]], [[4gr3]], [[4gr8]], [[4h30]], [[4h49]], [[4h76]], [[4h84]], [[4io3]], [[1jk3]],[[4efs]], [[4gql]], [[4gr0]], [[4gr3]], [[4gr8]], [[4guy]], [[4h30]], [[4h49]], [[4h76]], [[4h84]], [[4i03]], [[5cxa]], [[5czm]], [[5d2b]], [[5d3c]], [[5i0l]], [[5i2z]], [[5i3m]], [[5i43]], [[5i4o]], [[5l79]], [[5l7f]], [[5lab]] - hMMP catalytic domain (mutant) + inhibitor<br />
**[[3lk8]], [[3lik]], [[3lil]], [[3lir]], [[3ljg]], [[3nx7]], [[3lka]], [[3ehx]], [[3ehy]], [[3f15]], [[3f16]], [[3f17]], [[3f18]], [[3f19]], [[3f1a]], [[1y93]], [[1rmz]], [[1os2]], [[1os9]], [[2hu6]], [[3ts4]], [[3tsk]], [[3uvc]], [[4gql]], [[4gr0]], [[4gr3]], [[4gr8]], [[4h30]], [[4h49]], [[4h76]], [[4h84]], [[4io3]], [[1jk3]],[[4efs]], [[4gql]], [[4gr0]], [[4gr3]], [[4gr8]], [[4guy]], [[4h30]], [[4h49]], [[4h76]], [[4h84]], [[4i03]], [[5cxa]], [[5czm]], [[5d2b]], [[5d3c]], [[5i0l]], [[5i2z]], [[5i3m]], [[5i43]], [[5i4o]], [[5l79]], [[5l7f]], [[5lab]], [[6ekn]], [[6ela]], [[6enm]], [[6eox]], [[5n5k]], [[5n5j]] - hMMP catalytic domain (mutant) + inhibitor<br />
**[[2oxn]], [[2oxz]], [[2oxw]] - hMMP catalytic domain (mutant) + peptide<br />
**[[2oxn]], [[2oxz]], [[2oxw]] - hMMP catalytic domain (mutant) + peptide<br />
**[[2n8r]] - hMMP catalytic domain (mutant) + collagen peptide – NMR<br />
**[[2n8r]] - hMMP catalytic domain (mutant) + collagen peptide – NMR<br />
Line 136: Line 138:
**[[3c7x]] – hMMP hemopexin-like domain<br />
**[[3c7x]] – hMMP hemopexin-like domain<br />
**[[2mqs]] - hMMP + collagen<br />
**[[2mqs]] - hMMP + collagen<br />
**[[5h0u]] - hMMP + polyHis<br />


*MMP16 Membrane T3
*MMP16 Membrane T3

Revision as of 11:41, 5 August 2018


Function

Matrix metalloproteinases (MMP) are Zinc-dependent endopeptidases. MMP degrades extracellular matrix proteins. They are inhibited by proteases called tissue inhibitors of metalloproteinase (TIMP). The pro-MMP contains a pro-peptide which must be removed to render the MMP active[1]. See details in

MMPs are produced by 28 different genes and are classified according to their protein substrates.

  • MMP1 cleaves collagens I, II, III, VII and X.
  • MMP2 cleaves collagen IV and denatured collagen.
  • MMP3 cleaves the core protein of aggrecan and plasminogen activator.
  • MMP7 cleaves proteoglycans, fibronectin, elastin and casein.
  • MMP8 cleaves aggrecan.
  • MMP9 cleaves gelatin. See details in Molecular Playground/MMP9
  • MMP10 cleaves collagens III, IV, V, fibronectin,gelatin and aggrecan.
  • MMP11 cleaves peptides in human tumors.
  • MMP12 cleaves collagens I and III. See details in Matrix Metalloproteinase 12
  • MMP13 cleaves collagen II and laminin-5 γ2.
  • MMP14 is a membrane-type MMP which cleaves aggrecan. See details in Molecular Playground/MMP14
  • MMP16 cleaves collagen III, proteoglycans, fibronectin, gelatin, vitronectin, laminin and α2-macroglobulin.
  • MMP20 cleaves E-cadherin.
  • MMP23 function is unknown.
  • MMP adamalysin is a snake toxin. See details in Atragin

Relevance

MMPs have a role in cancer progression[2]. MMP-2 and MMP-9 secretion is elevated in ovarian cancer and are associated with poor prognosis[3]. MMP-8, MMP-9, MMP-13 and MMP-14 have a role in periodontal diseases[4].

MT1-MMP-TIMP-1 complex

The human matrix metalloproteinases (MMPs) family comprises a large group of structurally homologous zinc-dependent endopeptidases (e.g. (darkmagenta) and (magenta), ) that perform a wide variety of biological roles. In general, the MMPs are inhibited unselectively by all four known tissue inhibitors of metalloproteinases (TIMPs 1-4) which have 40-50% sequence identity. For example, can form complex with (1uea, colored orange). (cyan) is mainly composed of the N-terminal segment that approaches the active site, the AB loop (Thr33-Tyr35), the CD loop (Ala65-Cys70), and the EF loop (Thr97-Ser100). The pivotal residue, threonine 98 (Thr98), is shown as red sticks. In general, (Cys1-Ser68, Val69-Met66, Gly71-Met66, Cys70-Glu67, and Cys70-Thr98) are intimately involved in the conformational stability of TIMP binding interface when bound to MMP.

(darkmagenta) also forms complex with (2j0t, colored orange), producing as well as . This network of hydrogen bonds stabilizes the CD and EF loops that compose the binding interface. Importantly, the . However, this MT1-MMP-WT-TIMP-1 complex is not tight-binding. MT1-MMP is unique since even though it exhibits high structural homology to all MMPs, it is not inhibited by TIMP-1, (1bqq). (mutant TIMP-1 is colored in yellow with T98L shown in red) transformed TIMP-1 into a high affinity inhibitor of MT1-MMP (3ma2). WT-TIMP-1, WT-TIMP-2, and TIMP-1 T98L mutant have kinetic dissociation binding constant (KD) 1.53 x 10-6, 5.61 x 10-8, and 8.70 x 10-8, respectively. So, KD of WT-TIMP-2 is 2 orders of magnitude smaller than that of WT-TIMP-1, indicating the weak affinity between MT1-MMP and WT-TIMP-1. The TIMP-1 T98L mutant regained high-affinity binding to MT1-MMP, resulting in a 2 order of magnitude decrease in KD, similar to the case for WT-TIMP-2, the in vivo inhibitor of MT1-MMP. The overall structures of the complexes of MT1-MMP-WT-TIMP-1 and MT1-MMP-mutant-T98L-TIMP-1 are . Even the structure of MT3-MMP-WT-TIMP-1 is (with wild-type and TIMP-1 T98L mutant). , which is situated near the MT1-MMP . So, this T98L replacement may stabilize the entire area by establishing a strong hydrophobic core upon binding to the enzyme. However, it seems unlikely that these additional bonds could account for the entire binding effect between MT1-MMP and TIMP-1. Statistical analysis of the stabilities in the TIMP-1 T98L mutant reveals that the hydrogen bonds network in mutant form is significantly more stable than that in WT-TIMP-1. Mutations that enhance hydrogen bond stability contribute to the stability of the bound-like, less flexible, conformation of TIMP-1, which eventually results in increasing binding affinity for MT1-MMP. Thus, mutation affected the instrinsic dynamics of the inhibitor rather than its structure, thereby facilitating the interaction [5].

Complex of MMP14 (magenta) and TIMP-1 (orange) with Ca+2 (green) and Zn+2 (grey) ions (PDB code 3ma2)

Drag the structure with the mouse to rotate

3D structures of matrix metalloproteinase3D structures of matrix metalloproteinase

Updated on 05-August-2018

ReferencesReferences

  1. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem. 1999 Jul 30;274(31):21491-4. PMID:10419448
  2. Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J. 2011 Jan;278(1):16-27. doi: 10.1111/j.1742-4658.2010.07919.x. Epub 2010, Nov 19. PMID:21087457 doi:http://dx.doi.org/10.1111/j.1742-4658.2010.07919.x
  3. Roomi MW, Monterrey JC, Kalinovsky T, Rath M, Niedzwiecki A. Patterns of MMP-2 and MMP-9 expression in human cancer cell lines. Oncol Rep. 2009 May;21(5):1323-33. PMID:19360311
  4. Birkedal-Hansen H. Role of matrix metalloproteinases in human periodontal diseases. J Periodontol. 1993 May;64(5 Suppl):474-84. PMID:8315570 doi:http://dx.doi.org/10.1902/jop.1993.64.5s.474
  5. Grossman M, Tworowski D, Dym O, Lee MH, Levy Y, Murphy G, Sagi I. Intrinsic protein flexibility of endogenous protease inhibitor TIMP-1 controls its binding interface and effects its function. Biochemistry. 2010 Jun 14. PMID:20545310 doi:10.1021/bi902141x

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

Michal Harel, Alexander Berchansky